The estimated Net Worth of Steinar J Engelsen is at least $23.6 Milion dollars as of 1 November 2021. Steinar Engelsen owns over 14,235 units of Insmed Inc stock worth over $23,341,554 and over the last 22 years he sold INSM stock worth over $0. In addition, he makes $272,500 as Independent Director at Insmed Inc.
Steinar has made over 8 trades of the Insmed Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he bought 14,235 units of INSM stock worth $429,043 on 1 November 2021.
The largest trade he's ever made was buying 109,337 units of Insmed Inc stock on 23 March 2011 worth over $554,339. On average, Steinar trades about 5,610 units every 146 days since 2003. As of 1 November 2021 he still owns at least 320,802 units of Insmed Inc stock.
You can see the complete history of Steinar Engelsen stock trades at the bottom of the page.
Dr. Steinar J. Engelsen M.D. serves as Independent Director of the Company. Dr. Engelsen is a partner of Teknoinvest AS frim 1996. Dr. Engelsen has been a member of our Board since our inception in November 1999 and was a director of Insmed Pharmaceuticals, our predecessor entity, from 1998 to 2000. Since November 1996, Dr. Engelsen has been a partner of Teknoinvest AS, a venture capital firm based in Norway. In addition, from January to November 2000, Dr. Engelsen was acting chief executive officer of Centaur Pharmaceuticals, Inc., a biopharmaceutical company. From 1989 until 1996, Dr. Engelsen held various management positions within Hafslund Nycomed AS, a pharmaceutical company based in Europe, and its affiliated companies. He was responsible for therapeutic research and development, serving as Senior Vice President, Research and Development of Nycomed Pharma AS from 1994 until 1996. Dr. Engelsen also serves on the board of directors of Capnia, Inc. (Nasdaq: CAPN), a medical device company. Dr. Engelsen holds a Master of Science degree in nuclear chemistry and a Doctor of Medicine degree from the University of Oslo and is a Certified European Financial Analyst. Dr. Engelsen has more than 25 years of experience in the pharmaceutical industry, including his experience as a financial analyst and as an investor in biopharmaceutical companies. The Board believes that Dr. Engelsen's finance and management experience as well as his public company board experience in biopharmaceutical companies enables him to provide operating insights.
As the Independent Director of Insmed Inc, the total compensation of Steinar Engelsen at Insmed Inc is $272,500. There are 13 executives at Insmed Inc getting paid more, with William Lewis having the highest compensation of $7,175,090.
Steinar Engelsen is 70, he's been the Independent Director of Insmed Inc since 1999. There are no older and 23 younger executives at Insmed Inc.
Steinar's mailing address filed with the SEC is 700 US HIGHWAY 202/206, , BRIDGEWATER, NJ, 08807.
Over the last 22 years, insiders at Insmed Inc have traded over $46,121,705 worth of Insmed Inc stock and bought 1,080,212 units worth $8,226,993 . The most active insiders traders include Llc Fmr, William Lewis oraz Dennis M Lanfear. On average, Insmed Inc executives and independent directors trade stock every 38 days with the average trade being worth of $2,452,158. The most recent stock trade was executed by Orlov S Nicole Schaeffer on 10 September 2024, trading 37,575 units of INSM stock currently worth $407,689.
insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. the company is dedicated to developing and bringing to market therapies that make a real difference in patients’ lives, while striving to understand and enhance the entire patient experience, from diagnosis and treatment to everyday living. headquartered in bridgewater, nj, we are a rapidly growing company with offices in seven countries.
Insmed Inc executives and other stock owners filed with the SEC include: